Prevention of cisplatin nephrotoxicity by exogenous atrial natriuretic peptide.

Deegan PM, Basinger MA, Jones MM, Hande KR
Toxicology. 1996 106 (1-3): 159-66

PMID: 8571387 · DOI:10.1016/0300-483x(95)03182-f

The ability of atrial natriuretic peptide (ANP) to prevent cisplatin-induced nephrotoxicity was compared to the protective effect of 3% NaCl. ANP (1 microgram/kg/min), 3% NaCl or peptide buffer vehicle (50 microliters/min) were infused for 45 min to conscious unrestrained rats immediately after cisplatin administration (5 mg/kg i.v.). Measurements taken 72 h after drug treatment indicated that compared to animals receiving cisplatin only, ANP co-treated rats had lower post-treatment plasma creatinine concentrations (0.70 +/- 0.07 vs 1.3 +/- 0.17 mg/dl; P < 0.05), blood urea nitrogen (BUN) concentrations (44.2 +/- 5.8 vs. 65.5 +/- 2.1 mg/dl; P < 0.05) and higher post-treatment glomerular filtration rates (GFR) (0.71 +/- 0.18 vs. 0.14 +/- 0.03 ml/min; P < 0.05). ANP was as effective as 3% NaCl in preventing cisplatin nephrotoxicity in this model. The effect of ANP co-treatment on the anti-tumor activity of cisplatin was also examined using the Walker 256 carcinosarcoma model. ANP treatment did not result in any observable loss in anti-tumor activity. When ANP was administered 72 h after cisplatin treatment, improvement in GFR was observed for the duration of the infusion, confirming the beneficial effect of ANP on cisplatin-damaged kidneys. ANP may have a role in the treatment and prevention of cisplatin nephrotoxicity especially in clinical situations where treatment with a large fluid volume is contraindicated.

MeSH Terms (16)

Animals Antineoplastic Agents Atrial Natriuretic Factor Blood Urea Nitrogen Carcinoma 256, Walker Cisplatin Creatinine Drug Interactions Glomerular Filtration Rate Kidney Kidney Diseases Male Rats Rats, Sprague-Dawley Renal Circulation Sodium Chloride

Connections (1)

This publication is referenced by other Labnodes entities: